{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:14:28Z","timestamp":1788516868791,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jamda.2026.106365","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:10:14Z","timestamp":1783393814000},"page":"106365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Drug-Drug Interactions With Nirmatrelvir\/Ritonavir Among Long-Term Care Facility Residents"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0604-5595","authenticated-orcid":false,"given":"Marzan A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Daiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemalkumar B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chia (Sam)","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"McConeghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2026.106365_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamainternmed.2020.7968","article-title":"Risk factors associated with all-cause 30-Day mortality in nursing home residents with COVID-19","volume":"181","author":"Panagiotou","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jamda.2026.106365_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/phar.2860","article-title":"Potential drug-drug interactions among U.S. adults treated with nirmatrelvir\/ritonavir: a cross-sectional study of the National Covid Cohort Collaborative (N3C)","volume":"43","author":"Xiao","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jamda.2026.106365_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/cid\/ciae551","article-title":"Alleviation of COVID-19 symptoms and reduction in healthcare utilization among high-risk patients treated with Nirmatrelvir\/Ritonavir (NMV\/R): a phase 3 randomized trial","volume":"80","author":"Hammond","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jamda.2026.106365_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10887","article-title":"Clinical outcomes following treatment for COVID-19 with Nirmatrelvir\/Ritonavir and Molnupiravir among patients living in nursing homes","volume":"6","author":"Ma","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jamda.2026.106365_bib5","article-title":"Paxlovid (nirmatrelvir\/ritonavir) effectiveness against hospitalization and death in N3C: a target trial emulation study","author":"Hansen","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jamda.2026.106365_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug\u2013drug interactions between the COVID-19 antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and comedications","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jamda.2026.106365_bib7","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.jamda.2021.08.006","article-title":"COVID-19 incidence and mortality among long-term care facility residents and staff in South Carolina","volume":"22","author":"Resciniti","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2026.106365_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.5044","article-title":"Clinical risk and outpatient therapy utilization for COVID-19 in the Medicare population","volume":"5","author":"Wilcock","year":"2024","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.jamda.2026.106365_bib10","first-page":"195","article-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines","year":"2024","journal-title":"National Institutes of Health"},{"key":"10.1016\/j.jamda.2026.106365_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2025.106028","article-title":"The feasibility of safe and efficient administration of COVID-19 chemoprophylaxis to nursing home residents","volume":"27","author":"Milner","year":"2026","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2026.106365_bib12","first-page":"325","article-title":"Influence of a short course of ritonavir used as booster in antiviral therapies against SARS-CoV-2 on the exposure of Atorvastatin and Rosuvastatin","volume":"39","author":"Krohmer","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jamda.2026.106365_bib13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jamainternmed.2022.6834","article-title":"Safely prescribing Paxlovid: avoiding drug-drug interactions","volume":"183","author":"Culas","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jamda.2026.106365_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2023.12945","article-title":"Monoclonal antibody and oral antiviral treatment of SARS-CoV-2 infection in US nursing homes","volume":"330","author":"McGarry","year":"2023","journal-title":"JAMA"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861026002550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861026002550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:34:33Z","timestamp":1788514473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525861026002550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525861026002550"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2026.106365","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Drug-Drug Interactions With Nirmatrelvir\/Ritonavir Among Long-Term Care Facility Residents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2026.106365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Post-Acute and Long-Term Care Medical Association.","name":"copyright","label":"Copyright"}],"article-number":"106365"}}